Effect of pregnancy on the pharmacokinetics of antihypertensive drugs

Clinical Pharmacokinetics

Volumn 48, Issue 3, 2009, Pages 159-168

  Anderson, Gail D ^a   Carr, Darcy B ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CLONIDINE; DILTIAZEM; DIURETIC AGENT; ENALAPRIL; ENALAPRILAT; FUROSEMIDE; HYDRALAZINE; ISRADIPINE; LABETALOL; METHYLDOPA; METOPROLOL; NIFEDIPINE; PRAZOSIN; THIAZINE DERIVATIVE; VASODILATOR AGENT;

ABSENCE OF SIDE EFFECTS; AREA UNDER THE CURVE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; LACTATION; PLASMA VOLUME; POSTPARTUM HEMORRHAGE; PREGNANCY; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; THIRD TRIMESTER PREGNANCY;

ANTIHYPERTENSIVE AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HUMANS; HYPERTENSION; HYPERTENSION, PREGNANCY-INDUCED; LACTATION; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR;

EID: 65349188152     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200948030-00002     Document Type: Review

References (73)

1. Koonin LM, MacKay AP, Berg CJ, et al. Pregnancy-related mortality surveillance: United States, 1987-1990. MMWR CDC Surveill Summ 1997 Aug 8; 46 (4): 17-36
2. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000 Jul; 183 (1): S1-22
3. Rey E, LeLorier J, Burgess E, et al. Report of the Canadian Hypertension Society Consensus Conference: 3. Treatment of hypertensive disorders in pregnancy. CMAJ 1997 Nov 1; 157 (9): 1245-54
4. Coppage KH, Sibai BM. Treatment of hypertensive complications in pregnancy: current pharmaceutical design. Curr Pharm Des 2005; 11 (6): 749-57
5. Andrade SE, RaebelMA, Brown J, et al. Outpatient use of cardiovascular drugs during pregnancy. Pharmacoepidemiol Drug Saf 2008 Mar; 17 (3): 240-7
6. Ferrer RL, Sibai BM, Mulrow CD, et al. Management of mild chronic hypertension during pregnancy: a review. Obstet Gynecol 2000 Nov; 96 (5 Pt 2): 849-60
7. Abalos E, Duley L, SteynDW, et al. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. CochraneDatabase Syst Rev 2001; (2): CD002252
8. Magee LA, Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2003; (3): CD002863
9. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanisticbased approach. Clin Pharmacokinet 2005; 44 (10): 989-1008
10. Nakai A, Sekiya I, Oya A, et al. Assessment of the hepatic arterial and portal venous blood flows during pregnancy with Doppler ultrasonography. Arch Gynecol Obstet 2002 Jan; 266 (1): 25-9
11. Robson SC, Mutch E, Boys RJ, et al. Apparent liver blood flow during pregnancy: a serial study using indocyanine green clearance. Br J Obstet Gynaecol 1990 Aug; 97 (8): 720-4
12. Morgan DJ, Smallwood RA. Clinical significance of pharmacokinetic models of hepatic elimination. Clin Pharmacokinet 1990 Jan; 18 (1): 61-76
13. Dean M, Stock B, Patterson RJ, et al. Serum protein binding of drugs during and after pregnancy in humans. Clin Pharmacol Ther 1980 Aug; 28 (2): 253-61
14. Tsen LC, Tarshis J, Denson DD, et al. Measurements of maternal protein binding of bupivacaine throughout pregnancy. Anesth Analg 1999 Oct; 89 (4): 965-8
15. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002 Mar; 71 (3): 115-21
16. Davison JM, Dunlop W. Renal hemodynamics and tubular function normal human pregnancy. Kidney Int 1980 Aug; 18 (2): 152-61
17. Saavedra JA, Reid JL, Jordan W, et al. Plasma concentration of alphamethyldopa and sulphate conjugate after oral administration of methyldopa and intravenous administration of methyldopa and methyldopa hydrochloride ethyl ester. Eur J Clin Pharmacol 1975 Aug 14; 8 (6): 381-6
18. Barnett AJ, BobikA,Carson V, et al. Pharmacokinetics of methyldopa: plasma levels following single intravenous, oral and multiple oral dosage in normotensive and hypertensive subjects. Clin Exp Pharmacol Physiol 1977 Jul-Aug; 4 (4): 331-9
19. Magee LA. Treating hypertension in women of child-bearing age and during pregnancy. Drug Saf 2001; 24 (6): 457-74
20. Horvath JS, Phippard A, Korda A, et al. Clonidine hydrochloride: a safe and effective antihypertensive agent in pregnancy. Obstet Gynecol 1985 Nov; 66 (5): 634-8
21. Buchanan ML, Easterling TR, Carr DB, et al. Clonidine pharmacokinetics during pregnancy: an OPRU Network study [abstract]. Annual Meeting, American College of Clinical Pharmacy; 2007 Mar 21-24; Denver (CO)
22. Frisk-Holmberg M, Paalzow L, Edlund PO. Clonidine kinetics in man: evidence for dose dependency and changed pharmacokinetics during chronic therapy. Br J Clin Pharmacol 1981 Nov; 12 (5): 653-8
23. Cunningham FE, Baughman VL, Peters J, et al. Comparative pharmacokinetics of oral versus sublingual clonidine. J Clin Anesth 1994 Sep-Oct; 6 (5): 430-3
24. Easterling TR, Brateng D, Schmucker B, et al. Prevention of preeclampsia: a randomized trial of atenolol in hyperdynamic patients before onset of hypertension. Obstet Gynecol 1999 May; 93 (5 Pt 1): 725-33
25. Butters L, Kennedy S, Rubin PC. Atenolol in essential hypertension during pregnancy. BMJ 1990 Sep 22; 301 (6752): 587-9
26. Magee LA, Elran E, Bull SB, et al. Risks and benefits of beta-receptor blockers for pregnancy hypertension: overview of the randomized trials. Eur J Obstet Gynecol Reprod Biol 2000 Jan; 88 (1): 15-26
27. Easterling TR, Carr DB, Brateng D, et al. Treatment of hypertension in pregnancy: effect of atenolol on maternal disease, preterm delivery, and fetal growth. Obstet Gynecol 2001 Sep; 98 (3): 427-33
28. De Paco C, Kametas N, Rencoret G, et al. Maternal cardiac output between 11 and 13 weeks of gestation in the prediction of preeclampsia and small for gestational age. Obstet Gynecol 2008 Feb; 111 (2 Pt 1): 292-300
29. Hardman J, Endres L, Fischer P, et al. Pharmacokinetics of labetalol in pregnancy. Pharmacotherapy 2005; 25: 1493
30. Rubin PC, Butters L, Kelman AW, et al. Labetalol disposition and concentration-effect relationships during pregnancy. Br J Clin Pharmacol 1983 Apr; 15 (4): 465-70
31. Rogers RC, Sibai BM, Whybrew WD. Labetalol pharmacokinetics in pregnancy-induced hypertension.Am J Obstet Gynecol 1990 Feb; 162 (2): 362-6
32. Jeong H, Choi S, Song JW, et al. Regulation of UDP- glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica 2008 Jan; 38 (1): 62-75
33. Sibai BM, Mabie WC, Shamsa F, et al. A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Gynecol 1990 Apr; 162 (4): 960-7
34. Hurst AK, Shotan A, Hoffman K, et al. Pharmacokinetic and pharmacodynamic evaluation of atenolol during and after pregnancy. Pharmacotherapy 1998 Jul-Aug; 18 (4): 840-6
35. Thorley KJ, McAinsh J, Cruickshank JM. Atenolol in the treatment of pregnancy- induced hypertension. Br J Clin Pharmacol 1981 Nov; 12 (5): 725-30
36. Hebert MF, Carr DB, Anderson GD, et al. Pharmacokinetics and pharmacodynamics of atenolol during pregnancy and postpartum. J Clin Pharmacol 2005; 45: 25-33
37. Hogstedt S, Lindberg B, Peng DR, et al. Pregnancy-induced increase in metoprolol metabolism. Clin Pharmacol Ther 1985 Jun; 37 (6): 688-92
38. Hogstedt S, Lindberg B, Rane A. Increased oral clearance of metoprolol in pregnancy. Eur J Clin Pharmacol 1983; 24 (2): 217-20
39. Lindeberg S, Holm B, Lundborg P, et al. The effect of hydralazine on steadystate plasma concentrations of metoprolol in pregnant hypertensive women. Eur J Clin Pharmacol 1988; 35 (2): 131-5
40. Lubbe WF, Hodge JV. Combined alpha- and beta-adrenoceptor antagonism with prazosin and oxprenolol in control of severe hypertension in pregnancy. NZ Med J 1981 Sep 9; 94 (691): 169-72
41. Rubin PC, Butters L, Low RA, et al. Clinical pharmacological studies with prazosin during pregnancy complicated by hypertension. Br J Clin Pharmacol 1983 Nov; 16 (5): 543-7
42. Bourget P, Fernandez H, Edouard D, et al. Disposition of a new ratecontrolled formulation of prazosin in the treatment of hypertension during pregnancy: transplacental passage of prazosin. Eur J Drug Metab Pharmacokinet 1995 Jul-Sep; 20 (3): 233-41
43. Wood AJ, Bolli P, Simpson FO. Prazosin in normal subjects: plasma levels, blood pressure and heart rate. Br J Clin Pharmacol 1976 Feb; 3 (1): 199-201
44. Prevost RR, Akl SA, Whybrew WD, et al. Oral nifedipine pharmacokinetics in pregnancy-induced hypertension. Pharmacotherapy 1992; 12 (3): 174-7
45. Barton JR, Prevost RR, Wilson DA, et al. Nifedipine pharmacokinetics and pharmacodynamics during the immediate postpartum period in patients with preeclampsia. Am J Obstet Gynecol 1991 Oct; 165 (4 Pt 1): 951-4
46. Ferguson 2nd JE, Schutz T, Pershe R, et al. Nifedipine pharmacokinetics during preterm labor tocolysis. Am J Obstet Gynecol 1989 Dec; 161 (6 Pt 1): 1485-90
47. Silberschmidt AL, Kuhn-Velten WN, Juon AM, et al. Nifedipine concentration in maternal and umbilical cord blood after nifedipine gastrointestinal therapeutic system for tocolysis. Br J Obstet Gynaecol 2008 Mar; 115 (4): 480-5
48. Marin TZ, Meier R, Kraehenmann F, et al. Nifedipine serum levels in pregnant women undergoing tocolysis with nifedipine. J Obstet Gynaecol 2007 Apr; 27 (3): 260-3
49. Schulz M, Schmoldt A. Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Die Pharmazie 2003 Jul; 58 (7): 447-74
50. Beely L. Adverse effects of drugs in later pregnancy. Clin Obstet Gynecol 1981; 24: 275-90
51. Carr DB, Gavrila D, Brateng D, et al. Maternal hemodynamic changes associated with furosemide treatment. Hypertens Pregnancy 2007; 26 (2): 173-8
52. Ponto LL, Schoenwald RD. Furosemide (frusemide): a pharmacokinetic/ pharmacodynamic review (part I). Clin Pharmacokinet 1990 May; 18 (5): 381-408
53. Riva E, Farina P, Tognoni G, et al. Pharmacokinetics of furosemide in gestosis of pregnancy. Eur J Clin Pharmacol 1978 Dec 18; 14 (5): 361-6
54. Tang BK, Kadar D, Qian L, et al. Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clin Pharmacol Ther 1991 Jun; 49 (6): 648-57
55. Begg EJ, Duffull SB, Hackett LP, et al. Studying drugs in human milk: time to unify the approach. J Hum Lact 2002 Nov; 18 (4): 323-32
56. Larsen LA, Ito S, Koren G. Prediction of milk/plasma concentration ratio of drugs. Ann Pharmacother 2003 Sep; 37 (9): 1299-306
57. Atkinson HC, Begg EJ. Prediction of drug distribution into human milk from physicochemical characteristics. Clin Pharmacokinet 1990 Feb; 18 (2): 151-67
58. Notarianni LJ, Belk D, Aird SA, et al. An in vitro technique for the rapid determination of drug entry into breast milk. Br J Clin Pharmacol 1995; 40: 333-7
59. Anderson GD. Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation. Expert Opin Drug Metab Toxicol 2006 Dec; 2 (6): 947-60
60. Schimmel MS, Eidelman AI, Wilschanski MA, et al. Toxic effects of atenolol consumed during breast feeding. J Pediatr 1989 Mar; 114 (3): 476-8
61. Atkinson HC, Begg EJ, Darlow BA. Drugs in human milk: clinical pharmacokinetic considerations. Clin Pharmacokinet 1988 Apr; 14 (4): 217-40
62. Kulas J, Lunell NO, RosingU, et al. Atenolol and metoprolol: a comparison of their excretion into human breast milk. Acta Obstet Gynecol Scand Suppl 1984; 118: 65-9
63. Devlin RG, Fleiss PM. Captopril in human blood and breast milk. J Clin Pharmacol 1981 Feb-Mar; 21 (2): 110-3
64. Bunjes R, Schaefer C, Holzinger D. Clonidine and breast-feeding. Clin Pharm 1993 Mar; 12 (3): 178-9
65. Hartikainen-Sorri AL, Heikkinen JE, Koivisto M. Pharmacokinetics of clonidine during pregnancy and nursing. Obstet Gynecol 1987 Apr; 69 (4): 598-600
66. OkadaM, Inoue H, Nakamura Y, et al. Excretion of diltiazem in human milk. N Engl J Med 1985 Apr 11; 312 (15): 992-3
67. Redman CW, Kelly JG,CooperWD. The excretion of enalapril and enalaprilat in human breast milk. Eur J Clin Pharmacol 1990; 38 (1): 99
68. Lunell NO, Kulas J, Rane A. Transfer of labetalol into amniotic fluid and breast milk in lactating women. Eur J Clin Pharmacol 1985; 28 (5): 597-9
69. Michael CA. Use of labetalol in the treatment of severe hypertension during pregnancy. Br J Clin Pharmacol 1979; 8 Suppl. 2: 211S-5S
70. White WB, Andreoli JW, Cohn RD. Alpha-methyldopa disposition in mothers with hypertension and in their breast-fed infants. Clin Pharmacol Ther 1985 Apr; 37 (4): 387-90
71. Penny WJ, Lewis MJ. Nifedipine is excreted in human milk. Eur J Clin Pharmacol 1989; 36 (4): 427-8
72. Manninen AK, Juhakoski A. Nifedipine concentrations in maternal and umbilical serum, amniotic fluid, breast milk and urine of mothers and offspring. Int J Clin Pharmacol Res 1991; 11 (5): 231-6
73. Davison JM, Hytten FE. Glomerular filtration during and after pregnancy. J Obstet Gynaecol Br Commonw 1974 Aug; 81 (8): 588-95